Sangamo Therapeutics (SGMO) Upgraded at BidaskClub

BidaskClub upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a hold rating to a buy rating in a research note published on Tuesday.

Several other research analysts have also commented on SGMO. ValuEngine upgraded shares of Sangamo Therapeutics from a buy rating to a strong-buy rating in a research note on Thursday, November 1st. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a strong sell rating to a hold rating in a research note on Tuesday, July 24th. Wedbush reiterated a hold rating and set a $9.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, July 24th. Guggenheim assumed coverage on shares of Sangamo Therapeutics in a research note on Tuesday, October 9th. They set a buy rating and a $18.00 price objective for the company. Finally, Cowen reissued a buy rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $21.00.

Shares of NASDAQ SGMO traded down $2.43 during trading hours on Tuesday, hitting $11.19. 191,033 shares of the stock were exchanged, compared to its average volume of 1,609,804. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.07. The firm has a market cap of $1.41 billion, a PE ratio of -16.06 and a beta of 3.21. Sangamo Therapeutics has a 12 month low of $11.65 and a 12 month high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. The firm had revenue of $23.56 million during the quarter, compared to analyst estimates of $26.96 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. Sangamo Therapeutics’s revenue was up 99.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.15) EPS. On average, equities research analysts anticipate that Sangamo Therapeutics will post -0.69 earnings per share for the current fiscal year.

In related news, Director H Stewart Parker bought 2,000 shares of the company’s stock in a transaction on Friday, September 7th. The shares were bought at an average price of $13.52 per share, with a total value of $27,040.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $13.73, for a total transaction of $68,650.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,000 shares of company stock worth $432,350. 1.20% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in shares of Sangamo Therapeutics by 20.8% in the 2nd quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock valued at $114,780,000 after acquiring an additional 1,391,067 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in shares of Sangamo Therapeutics by 12.0% in the 3rd quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock valued at $77,031,000 after acquiring an additional 486,429 shares during the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at $5,069,000. Nexthera Capital LP boosted its holdings in shares of Sangamo Therapeutics by 35.7% in the 2nd quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock valued at $15,150,000 after acquiring an additional 280,538 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Sangamo Therapeutics by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock valued at $11,218,000 after acquiring an additional 234,346 shares during the last quarter. 64.01% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Article: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply